



2250 Hickory Road, Suite 216 ■ Plymouth Meeting, PA 19462 ■ PHONE: 484.532.2200 ■ FAX: 610.828.4847

BioBDx Launches Portable Quotient® ADHD System

Plymouth Meeting, PA – September 14, 2011 – BioBehavioral Diagnostics Company (BioBDx) announced today the launch of a portable version of its Quotient ADHD System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is for the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).

The Quotient System directly and quantitatively measures the same neural control processes that are assessed subjectively by parent and teacher rating scales, the current standard for evaluating the symptoms of ADHD. This objective data helps physicians to perform better ADHD assessments and guide treatment decisions. Research has demonstrated that clinicians who conduct well-informed ADHD assessments using all available information achieve better outcomes for their patients with ADHD. The Quotient ADHD Test can help achieve this goal.

The portable Quotient ADHD System offers clinicians more flexibility than the original kiosk. Clinicians can now transport the system to other office locations, or offer ADHD test days at schools or health fairs. The compact size also enables space-constrained practices to implement objective ADHD testing.

“ADHD affects the lives of nearly 10 million US children, adolescents and adults, yet there remains a huge unmet need for more accurate and objective clinical tools,” said Byron Hewett, BioBDx Chairman and CEO. “It’s clear that access to objective, understandable information leads to better decisions in diagnosis and treatment management, and better decisions lead to better outcomes. The smaller size and easy portability of this new Quotient System makes this technology available to an even broader number of clinicians and patients throughout the country.”

About the Quotient ADHD System

The Quotient ADHD System measures micro-motion and analyzes impulsivity and shifts in attention state to give an objective and quantitative picture of the core symptom areas of ADHD. Clinicians use the Quotient ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity. Patients may be re-assessed periodically at follow-up visits to guide treatment plans. The clinician integrates the Quotient report with data from other assessment tools and the clinical evaluation to help inform diagnostic and therapeutic decisions and to guide discussions with patients and families on treatment plans. For more information about the Quotient ADHD System, please visit <http://www.BioBDx.com/products>

About BioBDx

BioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control. The

first FDA-cleared application of this platform technology is for the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD). The Company is dedicated to providing physicians, families and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine. Founded in 2006, BioBDx is a privately held company.

Contacts:

BioBDx:

Byron Hewett
Chairman and Chief Executive Officer
484-532-2201
Byron_Hewett@BioBDx.com

Media or Investors:

Tiberend Strategic Advisors, Inc.
212-827-0020
Claire Sojda
csojda@tiberend.com